FIELD: medicine.
SUBSTANCE: composition comprises (a) a delivery vehicle selected from the group consisting of a nanolipogel containing a polymeric core and a lipid shell and a biodegradable polymeric nanoparticle; and (b) IL-2 and losartan loaded into the delivery vehicle attached to its surface and / or enclosed in the delivery vehicle. Also, a method for increasing or improving the immunostimulatory or immunity-enhancing agent, stimulating the immune response is also provided, as well as a method for increasing or improving the chemotherapeutic action of a chemotherapeutic agent, a method for treating cancer.
EFFECT: group of inventions relates to medicine and relates to a pharmaceutical composition of nanoparticles intended for immunotherapy.
23 cl, 14 dwg, 1 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNE-MODIFYING PARTICLES FOR CANCER TREATMENT | 2019 |
|
RU2794261C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
| SILENSING OF TGF-BETA 1 AND Cox-2 USING siRNA DELIVERED IN A POLYPEPTIDE NANOPARTICLE, SINGLE AND IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF MALIGNANT NEOPLASM | 2019 |
|
RU2797510C2 |
| METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY | 2017 |
|
RU2755903C2 |
| PEPTIDE CONJUGATED PARTICLES | 2014 |
|
RU2685186C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-R[ALPHA] SUSHI DOMAIN | 2012 |
|
RU2644671C2 |
| THERAPEUTIC USE OF THE TLR AGONIST AND COMBINED THERAPY | 2011 |
|
RU2603467C2 |
| COMPOSITIONS AND METHODS OF ORGAN-PROTECTIVE EXPRESSION AND MODULATION OF ENCODING RIBONUCLEIC ACIDS | 2019 |
|
RU2803294C2 |
| ANTI-TUMOUR COMPOSITION | 2019 |
|
RU2768287C1 |
| CANCER IMMUNOTHERAPY | 2014 |
|
RU2744194C2 |
